ADIAL Pharmaceuticals removed a penalty provision from Warrant agreements and added lock-up restrictions on certain related common stock. The changes are intended to alter the accounting treatment of milestone warrant rights, which had reduced stockholders’ Equity below Nasdaq requirements, and support the company’s continued and initial listing compliance.

Key Highlights

  • ADIAL Pharmaceuticals acquired Azora Therapeutics on June 11, 2026, under a Merger agreement.
  • ADIAL Pharmaceuticals removed the Penalty Provision from the securities purchase and note exchange arrangements.
  • The Milestone Warrants had been classified as a liability, leaving stockholders’ equity below Nasdaq requirements.

ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) amended its warrant agreements on September 16, 2026, removing a penalty provision and adding lock-up terms. The change is intended to alter the accounting treatment of milestone warrant rights and support Nasdaq Capital Market compliance. Stockholder approval at the September 17, 2026, Annual Meeting concerns a preferred-stock conversion that will represent more than 19.99% of common stock outstanding immediately before the Merger Agreement.

Azora Deal Adds Preferred Stock and Warrants

ADIAL Pharmaceuticals acquired Azora Therapeutics, Inc. on June 11, 2026, under an Agreement and Plan of Merger. In exchange for Azora’s outstanding capital stock, it issued 437,474 common shares and 12,930.617 Series A Non-Voting Convertible Preferred Stock shares, with each preferred share convertible into 1,000 common shares. The PIPE transaction issued pre-funded warrants covering 9,749,345 common shares, while former Azora noteholders received warrants covering 2,031,603 common shares in exchange for extinguishing the company’s guarantee and retiring Azora Notes with a principal amount of $5,500,000.

Amendments Address Nasdaq Equity Requirements

A separate amendment with former Azora noteholders covered warrants for 1,504,098 common shares and imposed equivalent restrictions.